Patient P-02124
Therapy response
Unstable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
83%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 67 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient declined — Not now
- Day 78 GI-04 recommended — GI Support Protocol GI-04
- Day 79 Patient accepted — Started GI-04 in the companion
- Day 87 No meaningful change — GI Support Protocol GI-04
- Day 91 ME-01 recommended — Monitoring Escalation ME-01
- Day 92 Patient accepted — Started ME-01 in the companion
- Day 95 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 67.
Primary contributors, last 14 days
- Toxicity-16
- GI instability+7
- Nutritional resilience+6
- Inflammatory activity+3
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 71Declined by patient
- GI Support Protocol GI-04Day 78Result: no meaningful change
- Monitoring Escalation ME-01Day 91Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable5 min
worsening · -3.6 vs previous 14 d
Sleep duration
Wearable5.4 h
stable · +0.1 vs previous 14 d
Energy level
Daily log1.5/10
worsening · -0.3 vs previous 14 d
Steps
Wearable300
worsening · -413 vs previous 14 d
GI burden
Companion66.2/100
worsening · +9.8 vs previous 14 d
Adherence
Companion46.1 %
improving · +2.3 vs previous 14 d
Sleep quality
Wearable15.4/100
improving · +1.4 vs previous 14 d
Glucose, CGM daily mean
CGM158 mg/dL
stable · +1.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 9 from the failing basin, 79 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 71%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 71%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 71%
- More proteinGI -3.3 next day on high-intake days · n 23
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- Keep ultra-processed lowGI +3.4 next day on high-intake days · n 16
- Keep fat lowGI +2.9 next day on high-intake days · n 13
- Keep simple carbs lowGI +2.1 next day on high-intake days · n 17
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Ultra-processed food+3.4detractor · 95%
- Protein-3.3supporter · 95%
- Dietary fat load+2.9detractor · 95%
- Simple carbohydrates+2.1detractor · 79%
- Insoluble fibre+1.9detractor · 70%
- Histamine load+1.8detractor · 71%
- Alcohol+0.2no signal · 15%
- Caffeine-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 81 bpm
- Wearable300 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 66 and rising
- WearableSleep 5.4 h, below personal baseline
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 64
- WearableHRV 21 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 43/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 16 ms
- Sleep
- 5.3 h
- Steps
- 992
- Resting HR
- 82 bpm
Daily log: GI score 66, nutritional resilience 40, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02506 | 50% | S14 | SC-12 | no change | 32 |
| P-02542 | 49% | S14 | NP-02 | improved | 44 |
| P-02057 | 47% | S14 | GI-04 | improved | 47 |
| P-02505 | 46% | S14 | NP-02 | improved | 45 |
| P-02146 | 45% | S14 | ME-01 | improved | 33 |
| P-02118 | 43% | S14 | GI-04 | improved | 47 |
| P-02445 | 43% | S09 | GI-04 | improved | 43 |
| P-02574 | 43% | S14 | ME-01 | improved | 45 |
| P-02014 | 42% | S14 | GI-04 | improved | 48 |
| P-02132 | 42% | S14 | SC-12 | improved | 40 |
| P-02253 | 42% | S14 | NP-02 | no change | 41 |
| P-02628 | 42% | S14 | SC-12 | improved | 47 |